Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
PharmaRoth Labs, Inc. specializes in developing and manufacturing generic pharmaceuticals, primarily focusing on the North American market. The company has a competitive edge through its proprietary drug formulation technologies that enhance bioavailability and reduce production costs.
PharmaRoth generates revenue primarily through the sale of generic pharmaceuticals, leveraging its proprietary formulation technologies to offer cost-effective alternatives to branded drugs. The company also engages in contract manufacturing for third-party clients, providing a steady revenue stream.
Approval of new generic drugs by the FDA
Changes in healthcare regulations affecting drug pricing
Market share gains in key therapeutic areas
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes that could impact drug approval processes
Technological disruption in drug formulation and manufacturing
Intense competition from other generic manufacturers
Potential for price erosion in key therapeutic areas
Negative operating margins leading to liquidity concerns
High fixed costs associated with R&D and manufacturing facilities
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand for non-essential drugs may decline during recessions.
Interest rates affect PharmaRoth's cost of capital for financing R&D and manufacturing. Higher rates could increase financing costs, impacting profitability.
minimal - The company has a negative debt/equity ratio, indicating a lack of reliance on external debt financing.
value - Investors may be attracted to the potential for turnaround given the company's proprietary technologies and market position.
high - The stock has shown significant volatility, with a 90% drop in the past year.